Value and Market Access
A trusted leader in oncology real-world data and evidence generation, Flatiron supports life science partners in planning and executing real-world evidence (RWE) health economics and outcomes research (HEOR) studies, particularly in support of Health Technology Assessments (HTA).
Our track record
The global leader in oncology real-world evidence
30+ HTA submissions
Flatiron data is acknowledged as a globally renowned, high-quality, and comprehensive source of oncology data. It has been submitted to HTA bodies in Europe on more than 30 occasions, including to assess comparative effectiveness.
“A comprehensive data package, including Flatiron data, led to the approval of the first all-comer drug for cancer immunotherapy.”
Dominik Heinzmann, PhD
Former Global Head RWD Oncology & Hematology at Roche, on the approval of atezolizumab by the National Institute for Health and Care Excellence (NICE) in the UK during ResearchX
US and international data
Flatiron is transforming global cancer care and research with growing networks in 4 of the world’s largest oncology markets. We are building global, high-quality datasets in Japan, Germany and the United Kingdom that expand on our US data model to help answer important questions for patients across the globe.
High-impact research collaborations
Flatiron is leveraging ongoing collaborations with life science partners and HTA bodies including NICE to explore how Flatiron can address evidence gaps when evaluating new oncology medicines and inform HTA decision making.
Featured Research
Transporting comparative effectiveness evidence between countries: considerations for health technology assessment
Hear from Flatiron scientist, Blythe Adamson, PhD, MPH, as she dives into the research and discusses crucial aspects in Health Technology Assessment (HTA) covering aspects like effect modifiers, target populations, estimands, study samples, and the seamless integration of transportability into HTA processes.
New offering
RWE Solutions for Value and Market Access
Flatiron is widely recognized as a trusted and leading provider of real-world data in oncology. Flatiron's data has fueled submissions to HTA bodies since 2018 for a variety of use cases including modeling long-term survival and progression, characterizing patients, conditions, or care patterns, and estimating comparative effects of medicines. We are further strengthening our HTA offering by building new data sources in the UK and Germany.
Flatiron is committed to advancing HTA use cases, offering a suite of products, services, and forums to support life science partners globally.
The consortium to advance HTA decision making through RWE
In the rapidly evolving landscape of oncology, RWE is gaining importance, driven by guidance from HTA bodies and regulators. However, the lack of clarity on what constitutes good evidence leads to inconsistencies in valuing studies across and even within HTA bodies.
Flatiron is establishing a consortium, FLATIRON FORUM (Fostering Oncology RWE Uses and Methods), to collaborate with leading global life science companies. The consortium’s aim is to enable better decision-making through the exemplar use of RWE and research methods, to accelerate patient access to oncology therapies.
Looking for support in planning and executing value and market access studies with RWE?
Leveraging Flatiron’s deep expertise in oncology evidence generation and HTA decision making, we are biopharma's trusted global RWE partner for:
-
Characterizing natural history of disease
-
Long-term survival extrapolation
-
Indirect treatment comparison analyses
-
Reassessment of marketed drugs
-
High-impact research collaborations with biopharma companies and HTA bodies
Reach out for a custom approach—our data products and services can be flexibly configured.